IMMUNE CHECKPOINT INHIBITORS IN SOLID TUMORS: MECHANISMS, CLINICAL EFFICACY, BIOMARKER-GUIDED PATIENT SELECTION, AND IMMUNE-RELATED ADVERSE EVENTS. jmsi. 2026;5(03):1709-1714. doi:10.55640/